Safety and Efficiency of γδ T Cell Against Lung Cancer

Study Overview
=================
Brief Summary
-----------------
In this study, effects of γδT cells on human Lung Cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated

Detailed Description
-----------------
Lung tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment. NOTE: Originally, our designed proposal was to use autologous PBMCs from cancer patients to ex vivo expand Vγ9Vδ2-T cells, and then perform adoptive transfer therapy. However, PBMCs of majority of cancer patients could not be effectively expanded, including cell number, cell purity and cell function could not meet the requirements of reinfusion. Meanwhile, those patients could not tolerate 100ml of blood drawing for culture every 2   3 weeks. Therefore, we submitted new clinical study application to the ethical committee of the Fuda Hospital affiliated with Jinan University (Guangzhou, PR. China) by changing the autologous protocol with the allogeneic protocol. After the allogeneic protocol was approved, we adapted allogeneic cells instead of autologous in our subsequentially clinical study.

Official Title
-----------------
γδ T Cell Immunotherapy for Treatment of Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Procedure: Cryosurgery or IRE surgery
* Biological: γδ T cell
* Other: γδ T cells/ A Cryosurgery or IRE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 18-75 Karnofsky performance status >50 Diagnosis with Lung Cancer based on histology or the current accepted radiological measures Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive cryosurgery, IRE, gd T cells Life expectancy: Greater than 3 months Ability to understand the study protocol and a willingness to sign a written informed consent document Exclusion Criteria: Patients with other kinds of cancer History of coagulation disorders or anemia Patients with heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor | Procedure: Cryosurgery or IRE surgery<br>* Cryosurgery or IRE surgery will be used in local tumor<br>|
| Experimental: Group B<br>In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell) | Biological: γδ T cell<br>* γδ T cells will be used against Lung Cancer<br>|
| Experimental: Group C<br>In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery | Other: γδ T cells/ A Cryosurgery or IRE<br>* Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relief degree of tumors | It will be evaluated by the Response Evaluation Criteria in Solid Tumors | 3 months | 
| Progress free survival（PFS) |  | 1 year | 
| Overall survival（OS） |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunotherapy, γδ T Cell, Lung Cancer